Laurus Labs Share Price Rally: Q1FY27 Profit Jump And Growth Drivers
.webp)
Key Takeaways
- Laurus Labs share price rose 4.05% to Rs 1,666 in Monday’s session.
- Q1FY27 net profit jumped 126% YoY to Rs 368 crore on revenue of Rs 2,026 crore.
- EBITDA margin expanded to 31.8%, up 7 percentage points year over year.
- FII stake rose to 28% in the June quarter; the stock has gained about 45% in 3 months and about 92% in 1 year.
Laurus Labs share price rose on Monday as investors digested Laurus Labs’ Q1FY27 numbers, which showed a net profit up 126% year-on-year to Rs 368 crore on revenue of Rs 2,026 crore. The quarter also delivered EBITDA of Rs 644 crore and an EBITDA margin of 31.8%, up seven percentage points from a year ago. Gross margins climbed to 62.7%, buoyed by efficient cost management and stronger CDMO deliveries, while capex during the quarter was 19% of sales. With FY27 and FY28 expansion plans on track, the directional bias remains constructive for the stock.
According to Dr Satyanarayana Chava of Laurus Labs, We delivered record quarterly revenue along with improved profitability, driven by increasing commercial deliveries in CDMO and sustained performance in affordable medicines, with EBITDA margin at 31.8% and gross margin at 62.7%.
Reference :
1 : Economictimes
Laurus Labs Share Price Rally After Q1FY27 Profit Jump
The stock rose 4.05% to Rs 1,666 in Monday’s trading session, reflecting a robust reaction to the quarter’s numbers. Q1FY27 net profit rose 126% YoY to Rs 368 crore on revenue of Rs 2,026 crore, underscoring a strong top-line performance alongside margin improvements. The momentum is part of a broader uptrend with approximately 45% gains in the last three months and roughly 92% gains over the last year. Management attributed the earnings improvement to higher CDMO commercial deliveries and continued strength in the affordable medicines segment. EBITDA for the quarter stood at Rs 644 crore, with the EBITDA margin at 31.8% and gross margins at 62.7%, aided by disciplined cost control and favorable product mix. The company also highlighted capex discipline (19% of sales) and an on-track expansion roadmap for FY27 and FY28.
Laurus Labs Quarterly Results And Q1FY27 Highlights
From the quarterly disclosures, revenue from operations reached Rs 2,026 crore in Q1FY27, up from Rs 1,570 crore in Q1FY26. Net profit printed at Rs 368 crore, a 126% YoY jump, while EBITDA rose to Rs 644 crore. EBITDA margin expanded to 31.8%, and gross margins stood at 62.7%. Capex during the quarter was 19% of sales. FII stake rose from 25.82% to 28% in the June 2026 quarter, reflecting stronger institutional confidence. Management reiterated that the capex plans for FY27 and FY28 remain on schedule, with CDMO and affordable medicines continuing to be growth engines for the year ahead.
Laurus Labs CDMO Growth: The Primary Growth Driver
The key growth driver in Q1FY27 was the uptick in commercial CDMO projects, which supported higher revenue and helped sustain profitability. CDMO growth translated into expanding margins and a stronger top line as the company reinforced its manufacturing and development capabilities to capture higher-value contracts. In addition, Laurus Labs is entering into agreements to in-license two antibody-drug conjugates, a strategic step to broaden its late-stage pipeline. The final handover of a new land parcel is expected to support future expansion capacity for FY27 and FY28, reinforcing the company’s long-term growth trajectory.
Laurus Labs Stock Price Momentum: RSI And Moving Averages
Technically, the setup remains supportive. The 14-day RSI sits at 66.3, suggesting room for upside before hitting overbought territory. The stock is trading above all eight key SMAs, indicating a broad-based positive trend across short- and mid-term horizons. This favorable technical posture aligns with the fundamental strength seen in Q1FY27, particularly the CDMO-driven growth and the steady performance in affordable medicines. Traders should monitor continued momentum in CDMO project wins and any updates related to ADC licensing deals and capex execution. For deeper, institution-level stock research, consider Swastika's Sarthi AI stock assistant.
Expansion Plans And Future Growth Outlook: Capex And In-License Deals
Capex during Q1FY27 was 19% of sales, and Laurus Labs reiterates that its capex plan for FY27 and FY28 remains on schedule. The company is also entering into agreements to in-license two antibody-drug conjugates, expanding its late-stage pipeline and potential pricing power. The final land parcel handover will support expansion capacity and new product lines in the coming years. This expansion, combined with CDMO growth and sustained demand for affordable medicines, strengthens the growth narrative while requiring ongoing attention to cash flow generation and debt management as the year unfolds.
Investment Profile: FII Stance, Market Cap And What It Means For Investors
FII participation rose to 28% in the June 2026 quarter from 25.82%, signaling continued institutional interest. The market capitalization stood at approximately Rs 86,505 crore, reflecting the market’s assignment of a strong growth premium to Laurus Labs’ CDMO and affordable medicines franchise. The combination of a constructive technical setup (RSI and moving averages) with solid revenue growth and margin expansion supports a favorable view for investors with a longer horizon, while acknowledging the volatility typical of pharma outsourcing cycles. Investors should align this with their risk tolerance and investment goals.
Frequently Asked Questions
What were Laurus Labs Q1FY27 revenue and net profit?
Revenue from operations was Rs 2,026 crore in Q1FY27, up from Rs 1,570 crore in Q1FY26. Net profit rose 126% YoY to Rs 368 crore.
What drove Laurus Labs' strong Q1FY27 performance?
Growth drivers included increased commercial projects in the CDMO segment and sustained momentum in the affordable medicines portfolio.
What is Laurus Labs' stock price momentum and technical picture after Q1FY27?
The stock gained about 4.05% to Rs 1,666 in the session following the results. The 14-day RSI stood at 66.3, and the stock traded above all eight key SMAs.
What expansion plans did Laurus Labs announce for FY27 and FY28?
Capex during the quarter was 19% of sales, and management stated that capex plans for FY27 and FY28 remain on schedule. The company is in-licensing two antibody-drug conjugates and completed the handover of a new land parcel to support expansion.
What is the market backdrop for Laurus Labs as of the June 2026 quarter?
FII stake rose to 28% in the June 2026 quarter, and the market capitalization was about Rs 86,505 crore, reflecting strong investor interest in Laurus Labs' CDMO and affordable medicines franchises.
Conclusion
From a retail-investor standpoint, the Q1FY27 results reinforce Laurus Labs as a CDMO-led growth play with improving profitability and a disciplined capex trajectory. The momentum in CDMO projects, the licensing of two antibody-drug conjugates, and the completion of expansion-capacity investments position the company well to monetize higher-value contracts in the years ahead. While valuations may reflect the growth premium, the combination of robust top-line growth, expanding margins, and a constructive technical backdrop provides a compelling setup for investors who can tolerate near-term volatility tied to macro and regulatory dynamics.
.avif)
.avif)
.avif)
